文献速递血栓与止血

生物物理研究未揭示人PF4与Ad26.COV2.S疫苗之间的直接相互作用

Biophysical studies do not reveal direct interactions between human PF4 and Ad26.COV2.S vaccine.
PubMed 文献 · J Thromb Haemost · 2023-12-29

研究采用动态光散射、生物层干涉和表面等离子共振技术,检测人血小板因子4(PF4)与Ad26.COV2.S疫苗的直接结合。动态光散射和生物层干涉未检测到直接相互作用,表面等离子共振不适用于此类研究。作者认为PF4直接结合疫苗驱动疫苗诱导免疫性血栓性血小板减少症(VITT)的可能性很小,但不能排除免疫后由未知血浆或细胞因子促进的相互作用。

要点

  • 动态光散射和生物层干涉未检测到PF4与Ad26.COV2.S疫苗直接结合。
  • 表面等离子共振被证明不适合研究此类相互作用。
  • 作者认为PF4直接结合疫苗驱动VITT的可能性很小,但不能排除免疫后间接相互作用。

核心结论

  • 作者认为PF4直接结合Ad26.COV2.S疫苗或其组分驱动VITT发生的可能性很小,但不能排除免疫后(可能由未知血浆或细胞因子促进)发生此类相互作用。
  • 需要进一步研究以增进对该不良反应完整机制的理解。

研究设计与样本

  • 研究采用动态光散射、生物层干涉和表面等离子共振技术,检测人PF4与Ad26.COV2.S疫苗的直接相互作用。
  • 在两种生物传感方法中,Ad26.COV2.S疫苗被固定于传感器表面,PF4作为分析物。

主要发现

  • 动态光散射和生物层干涉未检测到PF4与Ad26.COV2.S疫苗之间的直接相互作用。
  • 表面等离子共振技术被证明不适合研究此类相互作用。

局限性

  • 作者指出不能排除免疫后(可能由未知血浆或细胞因子促进)发生PF4与Ad26.COV2.S疫苗相互作用。
  • 作者指出需要进一步研究以增进对该不良反应完整机制的理解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: COVID-19 vaccines have been widely used to control the SARS-CoV-2 pandemic. In individuals receiving replication-incompetent, adenovirus vector-based COVID-19 vaccines (eg, ChAdOx1 nCoV-19 [AstraZeneca] or Ad26.COV2.S [Johnson & Johnson/Janssen] vaccines), a very rare but serious adverse reaction has been reported and described as vaccine-induced immune thrombotic thrombocytopenia (VITT). The exact mechanism of VITT following Ad26.COV2.S vaccination is under investigation. Antibodies directed against human platelet factor 4 (PF4) are considered critical in the pathogenesis of VITT, suggesting similarities with heparin-induced thrombocytopenia. It has been postulated that components of these vaccines mimic the role of heparin by binding to PF4, triggering production of these anti-PF4 antibodies. OBJECTIVES: This study aimed to investigate the potential interaction between human PF4 and Ad26.COV2.S vaccine using several biophysical techniques. METHODS: Direct interaction of PF4 with Ad26.COV2.S vaccine was investigated using dynamic light scattering, biolayer interferometry, and surface plasmon resonance. For both biosensing methods, the Ad26.COV2.S vaccine was immobilized to the sensor surface and PF4 was used as analyte. RESULTS: No direct interactions between PF4 and Ad26.COV2.S vaccine could be detected using dynamic light scattering and biolayer interferometry. Surface plasmon resonance technology was shown to be unsuitable to investigate these types of interactions. CONCLUSION: Our findings make it very unlikely that direct binding of PF4 to Ad26.COV2.S vaccine or components thereof is driving the onset of VITT, although the occurrence of such interactions after immunization (potentially facilitated by unknown plasma or cellular factors) cannot be excluded. Further research is warranted to improve the understanding of the full mechanism of this adverse reaction.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. van der Neut Kolfschoten M, Inganäs H, Perez-Peinado C, et al. Biophysical studies do not reveal direct interactions between human PF4 and Ad26.COV2.S vaccine. J Thromb Haemost. 2023. PMID: 38159648. doi:10.1016/j.jtha.2023.12.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。